CL2022002520A1 - Anticuerpos anti-sea de muc1 - Google Patents

Anticuerpos anti-sea de muc1

Info

Publication number
CL2022002520A1
CL2022002520A1 CL2022002520A CL2022002520A CL2022002520A1 CL 2022002520 A1 CL2022002520 A1 CL 2022002520A1 CL 2022002520 A CL2022002520 A CL 2022002520A CL 2022002520 A CL2022002520 A CL 2022002520A CL 2022002520 A1 CL2022002520 A1 CL 2022002520A1
Authority
CL
Chile
Prior art keywords
antibodies
muc1
sea antibodies
muc1 anti
sea
Prior art date
Application number
CL2022002520A
Other languages
English (en)
Inventor
Rubinstein Daniel
Wreschner Daniel
Original Assignee
Biomodifying Llc
Univ Ramot
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomodifying Llc, Univ Ramot filed Critical Biomodifying Llc
Publication of CL2022002520A1 publication Critical patent/CL2022002520A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

La presente invención proporciona anticuerpos monoclonales aislados que se unen al dominio SEA de MUC1. La invención se refiere, además, al uso de estos anticuerpos en métodos terapéuticos y de diagnóstico
CL2022002520A 2020-03-18 2022-09-15 Anticuerpos anti-sea de muc1 CL2022002520A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062991077P 2020-03-18 2020-03-18

Publications (1)

Publication Number Publication Date
CL2022002520A1 true CL2022002520A1 (es) 2023-03-10

Family

ID=75439163

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022002520A CL2022002520A1 (es) 2020-03-18 2022-09-15 Anticuerpos anti-sea de muc1

Country Status (18)

Country Link
US (1) US20230085269A1 (es)
EP (1) EP4087879A1 (es)
JP (1) JP2023517754A (es)
KR (1) KR20220161267A (es)
CN (1) CN115667312A (es)
AU (1) AU2021239078A1 (es)
BR (1) BR112022018629A2 (es)
CA (1) CA3171531A1 (es)
CL (1) CL2022002520A1 (es)
CO (1) CO2022014726A2 (es)
CR (1) CR20220523A (es)
CU (1) CU20220055A7 (es)
DO (1) DOP2022000193A (es)
EC (1) ECSP22080687A (es)
IL (1) IL296572A (es)
MX (1) MX2022011553A (es)
PE (1) PE20230602A1 (es)
WO (1) WO2021186427A1 (es)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006209246A1 (en) * 2005-01-28 2006-08-03 Biomodifying Llc Anti-MUC1 alpha/beta antibodies
BR112019019650A2 (pt) * 2017-03-21 2020-06-30 Peptron, Inc. ligação de anticorpos especificamente à muc1 e utilização dos mesmos

Also Published As

Publication number Publication date
US20230085269A1 (en) 2023-03-16
CA3171531A1 (en) 2021-09-23
AU2021239078A1 (en) 2022-08-11
CN115667312A (zh) 2023-01-31
WO2021186427A1 (en) 2021-09-23
DOP2022000193A (es) 2023-03-23
IL296572A (en) 2022-11-01
EP4087879A1 (en) 2022-11-16
PE20230602A1 (es) 2023-04-10
CR20220523A (es) 2023-01-23
MX2022011553A (es) 2023-01-04
BR112022018629A2 (pt) 2023-03-07
KR20220161267A (ko) 2022-12-06
ECSP22080687A (es) 2022-12-30
CU20220055A7 (es) 2023-06-13
CO2022014726A2 (es) 2023-02-16
JP2023517754A (ja) 2023-04-26

Similar Documents

Publication Publication Date Title
CL2020002305A1 (es) Uso de anticuerpos sirpa v1 antihumanos y procedimiento de producción de anticuerpos anti-sirpa v1
ECSP19078429A (es) Anticuerpos anti-trem2 y métodos para utilizarlos
EA202092825A1 (ru) Анти-sirpa антитела и способы их применения
PE20200757A1 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
EA201792221A1 (ru) Антитела против сортилина и способы их применения
CL2021000089A1 (es) Anticuerpos anti -sortilina y métodos para su uso.
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
MX2020009861A (es) Anticuerpos contra el complejo principal de histocompatibilidad relacionado con las cadenas a y b clase i (mica) y/o (micb) y sus usos.
CL2021001260A1 (es) Anticuerpos anti-sirpa humanizados
EA201892716A1 (ru) Антитела к фактору свертывания xi
CL2021000258A1 (es) Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
EA201992316A1 (ru) Композиции и способы для диагностики рака предстательной железы
EA202092085A1 (ru) ТЕРАПЕВТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ sPLA2-GIB И ИХ ПРИМЕНЕНИЕ
EA202190235A1 (ru) Антитела к cd33 и способы их применения
CO2021000046A2 (es) Anticuerpos de unión a vista a ph ácido
MX2021003673A (es) Anticuerpos anti-vsig4 humano y usos de los mismos.
BR112022012093A2 (pt) Anticorpos contra integrina alfa 11 beta 1
AR081321A1 (es) N-cadherina: un blanco para el diagnostico y la terapia del cancer
EA201992317A1 (ru) Композиции и способы для диагностики рака легких
EA201891529A1 (ru) Композиции и способы обнаружения и лечения рака яичников
BR112021010634A2 (pt) Anticorpos antiperiostina e usos dos mesmos
CL2022002520A1 (es) Anticuerpos anti-sea de muc1
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
CO2022002937A2 (es) Anticuerpos de unión a vista a ph ácido
EA201992886A1 (ru) Активируемые антитела против pdl1 и способы их применения